Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions
Interventions
BIC
F/TAF
+4 more
Locations
21
United States
Phoenix, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Washington D.C., District of Columbia, United States
Washington D.C., District of Columbia, United States
Start Date
March 23, 2015
Primary Completion Date
November 30, 2015
Completion Date
February 27, 2019
Last Updated
April 7, 2020
NCT06660498
NCT06602622
NCT06185452
NCT06902038
NCT04568603
NCT01511809
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions